Functional interaction between acyl-CoA synthetase 4, lipooxygenases and cyclooxygenase-2 in the aggressive phenotype of breast cancer cells

• Published in: PloS one Vol. 5; no. 11; p. e15540
• Main Authors: Maloberti, Paula M, Duarte, Alejandra B, Orlando, Ulises D, Pasqualini, María E, Solano, Angela R, López-Otín, Carlos, Podestá, Ernesto J
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 11.11.2010; Public Library of Science (PLoS)
• Subjects: Aggressive behavior; Antibiotics; Apoptosis; Arachidonate 12-Lipoxygenase - genetics; Arachidonate 12-Lipoxygenase - metabolism; Arachidonic acid; Arachidonic Acid - metabolism; Biochemistry; Biology; Biosynthesis; Blotting, Western; Breast cancer; Breast Neoplasms - enzymology; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Cancer; Cancer cells; Cell cycle; Cell growth; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coenzyme A Ligases - genetics; Coenzyme A Ligases - metabolism; Colon; Colon cancer; COX-2 inhibitors; Cyclooxygenase 2 - genetics; Cyclooxygenase 2 - metabolism; Cyclooxygenase-2; Drugs; Enzymes; Esterification; Fatty acids; Fatty Acids - metabolism; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic aspects; Genotype & phenotype; Hepatocellular carcinoma; Humans; Intracellular levels; Kinases; Ligases; Lipoxygenases - genetics; Lipoxygenases - metabolism; Liver cancer; Medicine; Metabolism; Metabolites; Metastases; Metastasis; Mitochondria; Mitochondria - metabolism; Motility; Phosphorylation; Physiological aspects; Prostaglandins - metabolism; Proteins; Regulation; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Rodents; Side effects; Trends; Tumorigenesis
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0015540

The acyl-CoA synthetase 4 (ACSL4) is increased in breast cancer, colon and hepatocellular carcinoma. ACSL4 mainly esterifies arachidonic acid (AA) into arachidonoyl-CoA, reducing free AA intracellular levels, which is in contradiction with the need for AA metabolites in tumorigenesis. Therefore, the causal role of ACSL4 is still not established. This study was undertaken to determine the role of ACSL4 in AA metabolic pathway in breast cancer cells. The first novel finding is that ACSL4 regulates the expression of cyclooxygenase-2 (COX-2) and the production of prostaglandin in MDA-MB-231 cells. We also found that ACSL4 is significantly up-regulated in the highly aggressive MDA-MB-231 breast cancer cells. In terms of its overexpression and inhibition, ACSL4 plays a causal role in the control of the aggressive phenotype. These results were confirmed by the increase in the aggressive behaviour of MCF-7 cells stably transfected with a Tet-off ACSL4 vector. Concomitantly, another significant finding was that intramitochondrial AA levels are significantly higher in the aggressive cells. Thus, the esterification of AA by ACSL4 compartmentalizes the release of AA in mitochondria, a mechanism that serves to drive the specific lipooxygenase metabolization of the fatty acid. To our knowledge, this is the first report that ACSL4 expression controls both lipooxygenase and cyclooxygenase metabolism of AA. Thus, this functional interaction represents an integrated system that regulates the proliferating and metastatic potential of cancer cells. Therefore, the development of combinatory therapies that profit from the ACSL4, lipooxygenase and COX-2 synergistic action may allow for lower medication doses and avoidance of side effects.